Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tecartus led to durable remission in a majority of participants in a Phase II study.
Results from randomized clinical trials of the antiviral drug continue to show mixed results.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
Curing the virus was associated with a lower risk of liver cancer recurrence.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
How the idea for synthetic cells took Silicon Valley by storm
The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.